AbCellera Biologics Inc
Fermé
SecteurSoins de santé
5.53 2.22
Résumé
Variation du prix de l'action
24h
Min
5.42
Max
5.53
Revenu | -34M -43M |
|---|---|
Ventes | -37M 8.3M |
BPA | -0.14 |
Marge bénéficiaire | -519.122 |
Employés | 562 |
EBITDA | -23M -41M |
Recommandations | Achat Fort |
|---|---|
Prévisions sur 12 Mois | +69.98% upside |
Prochains Résultats | 6 août 2026 |
|---|
Capitalisation Boursière | 3.6M 1.6B |
|---|---|
Ouverture précédente | 3.31 |
Clôture précédente | 5.53 |
AbCellera Biologics Inc Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
À Propos AbCellera Biologics Inc
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
